[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100381651":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":41,"collaborators":45,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":7,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":7,"maxAge":7,"enrollmentInfo":61,"targetDuration":7,"studyType":64,"phases":7,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"University of British Columbia","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Bruce Carleton, PharmD.","CONTACT","604-875-2179","bcarleton@popi.ubc.ca",[15,31],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"Children's and Women's Health Centre of British Columbia","RECRUITING","Vancouver","British Columbia","V6H 3V4","Canada","CA",{"type":24,"coordinates":25},"Point",[26,27],-123.11934,49.24966,{"lat":27,"lon":26},[30],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"facility":32,"status":17,"city":33,"state":34,"zip":35,"country":21,"countryCode":22,"cosmosGeoPoint":36,"geoPoint":40,"contacts":7},"Children's Hospital of Eastern Ontario","Ottawa","Ontario","K1H 8L1",{"type":24,"coordinates":37},[38,39],-75.69812,45.41117,{"lat":39,"lon":38},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Bruce Carleton","Director, Pharmaceutical Outcomes Programme",[46,49,51],{"name":47,"class":48},"Genome British Columbia","INDUSTRY",{"name":50,"class":6},"Genome Canada",{"name":52,"class":53},"Dynacare Laboratories, Inc.","UNKNOWN","100381651","integrating-pediatric-pharmacogenomic-testing-into-the-canadian-health-care-system-100381651",false,"NCT04249375","Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System","Inclusion Criteria:\n\n* Participants will be enrolled if they can benefit from pharmacogenomic testing. This means their physician is considering the use of a drug that is part of the panels (analgesics, antibiotics, and mental health medication) or they are already using one.\n\nExclusion Criteria:\n\n* Patients who do not speak or understand English.","ALL",{"count":62,"type":63},150,"ESTIMATED","OBSERVATIONAL","This project addresses the problem of adverse drug reactions in the three most frequently prescribed therapeutic classes of drugs in children: antibiotics, analgesics, and mental health medications.\n\nWe will conduct pilot testing of a pharmacogenomic testing panel and study how the tests and generated test results are utilized and understood by physicians, pharmacists, patients and their families.",[67],"Adverse Drug Reaction (ADR)",[69,70,71],"Pharmacogenomics","Pediatrics","Adverse Drug Reactions","2026-04-27",{"date":74,"type":75},"2026-05-01","ACTUAL",{"date":77,"type":75},"2020-02-20",{"date":79,"type":63},"2028-03",{"name":5,"class":6},2]